Rekrutierende Studien
AARON
An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
MOSAIC
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
SEQUENCE
Sequential gilteritinib in combination with venetoclax and azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) and FLT3 mutations ineligible for intensive treatment.